Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

2.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

3.

Hematocrit Stabilized in Polycythemia Vera Under Novel Hepcidin Mimetic Treatment.

4.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

5.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot